A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. First-line FOLFOX plus ...
First FDA-approved CDx for Guardant360 CDx in colorectal cancer further expands its role in guiding targeted therapy across solid tumors Approval supported by data from Pfizer’s BREAKWATER trial ...
Braftovi plus Erbitux and FOLFIRI showed significant ORR benefits in BRAF V600E–mutant mCRC compared to the control regimen. The combination therapy achieved a confirmed ORR of 64.4% versus 39.2% with ...
Three-year disease-free survival after transanal vs. laparoscopic total mesorectal excision for rectal cancer (TaLaR): A randomized clinical trial. Uncovering actionable genetic alterations and immune ...
(RTTNews) - Guardant Health, Inc. (GH) said Thursday that the U.S. Food and Drug Administration has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with BRAF ...
The study showed that treatment with encorafenib and cetuximab plus mFOLFOX6 chemotherapy significantly improved objective response rate, progression-free survival, and overall survival compared with ...
CLEVELAND, Ohio — The benefits of getting regular exercise, combining two cancer drugs with chemotherapy, and using AI to ...
Editor’s Note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. I mentioned earlier that there was the ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results